natgillin/translations-raw huggingface dataset:
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours. 
Ta koristni učinek se je pojavil pri vseh starostih, obeh spolih in ob jemanju fibrinolitikov ali brez njega, opažen pa je bil že po 24 urah.
For the 28x1 tablets pack size, you can check the day on which you last took the tablet by referring to the calendar printed on the blister. 
Če uporabljate pakiranje 28 x 1 tableta, lahko dan, ko ste nazadnje vzeli tableto, preverite na koledarju odtisnjenem na pretisnem omotu.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group]. 
Ta korist je bila v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6%) v skupini, zdravljeni s klopidogrelom, in 363 (5,8%) v skupini s placebom].
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: 
Klopidogrel je indiciran pri odraslih za preprečevanje aterotrombotičnih dogodkov pri bolnikih z:
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04. 
Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
In another study it was shown that administering clopidogrel and omeprazole 12 hours apart did not prevent their interaction that is likely to be driven by the inhibitory effect of omeprazole on CYP2C19. 
Druga študija je pokazala, da uporaba klopidogrela in omeprazola v presledku 12 ur ne prepreči njunega medsebojnega delovanja, ki je verjetno posledica zavrtja CYP2C19 z omeprazolom.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
NSAID: v klinični študiji, na zdravih prostovoljcih je sočasno jemanje klopidogrela in naproksena povečalo prikrito krvavitev iz prebavil.
The co-primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death. 
Sestavljeni opazovani dogodki so bili smrt zaradi kateregakoli vzroka ali prvi pojav ponovnega infarkta, kapi ali smrt.
Hallucinations, confusion 
Psihiatrične motnje halucinacije, zmedenost
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain 
• če imate zdravstveno stanje, ki trenutno povzroča krvavitev, npr. rana na želodcu ali možganska krvavitev;
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed clopidogrel in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo klopidogrel v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other drugs, not all patients will have adequate platelet inhibition. 
Ker aktivni presnovek nastane z delovanjem encimov CYP450, od katerih so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, se ustrezno zavrtje trombocitov ne pojavi pri vseh bolnikih.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT. 
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST spojnice sta bili varnost in učinkovitost klopidogrela vrednoteni v dveh randomiziranih, s placebom kontroliranih, dvojno slepih študijah, CLARITY in COMMIT.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Peroralni antikoagulanti.
Pharmacogenetic testing can identify genotypes associated with variability in CYP2C19 activity. 
Farmakogenetsko testiranje lahko odkrije genotipe, povezane z variabilnostjo aktivnosti CYP2C19.
Data from studies with human liver microsomes indicated that the carboxylic acid metabolite of clopidogrel could inhibit the activity of Cytochrome P450 2C9. 
Podatki iz študij s humanimi jetrnimi mikrosomi kažejo, da lahko karboksilni kislinski presnovek klopidogrela zaustavi aktivnost citokroma P450 2C9.
To date, the impact of CYP2C19 genotype on the pharmacokinetics of the active metabolite of clopidogrel has been evaluated in 227 subjects from 7 reported studies. 
Doslej so vpliv genotipa CYP2C19 na farmakokinetiko aktivnega presnovka klopidogrela ocenili pri 227 preiskovancih v 7 opisanih študijah.
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Teva Generics B.V.. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden vzamete zdravilo Klopidogrel Teva Generics B.V..
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• Miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
The CYP2C19*2 and CYP2C19*3 alleles account for 85% of reduced function alleles in whites and 99% in Asians. 
Na račun alelov CYP2C19*2 in CYP2C19*3 gre 85% alelov z zmanjšanim delovanjem pri belcih in 99% pri Azijcih.
Film coating: 
Filmska obloga:
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy. 
Heparine so uporabljali pri več kot 90% bolnikov, sočasna uporaba heparinske terapije ni pomembno vplivala na relativni delež krvavitev med klopidogrelom in placebom.
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy. 
To je veljalo tudi za podskupine bolnikov, opredeljene z določenimi izhodiščnimi značilnostmi in tipom fibrinolitičnega ali heparinskega zdravljenja.
The association between CYP2C19 genotype and clopidogrel treatment outcome was evaluated in 2 post hoc clinical trial analyses (substudies of CLARITY [n=465] and TRITON-TIMI 38 [n=1,477]) and 5 cohort studies (total n=6,489). 
Povezavo med genotipom CYP2C19 in izidom zdravljenja s klopidogrelom so ocenili v 2 post hoc analizah kliničnih preskušanj (podštudiji CLARITY [n = 465] in TRITON-TIMI 38 [n = 1.477]) ter 5
Data from the CAPRIE study indicate that phenytoin and tolbutamide can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da je sočasno jemanje fenitoina in tolbutamida s klopidogrelom varno.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se pri zdravljenju več kot 3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostala (glejte poglavje 4.4).
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Klopidogrel je pomembno zmanjšal relativno tveganje za smrt zaradi kateregakoli vzroka za 7% (p=0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9% (p=0,002), kar je predstavljalo absolutno zmanjšanje za 0,5% oziroma 0,9%.
In TRITON-TIMI 38 and 3 of the cohort studies (n= 3,516; Collet, Sibbing, Giusti), patients with an impaired metaboliser status (intermediate and poor combined) had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers. 
V TRITON-TIMI 38 in 3 kohortnih študijah (n = 3.516; Collet, Sibbing, Giusti) so imeli bolniki s statusom nezadostnega presnavljalca (srednji in slabi presnavljalci skupaj) večji delež kardiovaskularnih dogodkov (smrt, miokardni infarkt, možganska kap) ali tromboze na opornici kot močni metabolizatorji.
The pharmacokinetics of the active metabolite of clopidogrel is not known in these special populations. 
Farmakokinetika aktivnega presnovka klopidogrela v teh posebnih skupinah bolnikov ni znana.
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness. 
Pri vsakem organskem sistemu so neželeni učinki navedeni po padajoči resnosti.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor. 
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina, ki je prisotna v številnih zdravilih proti bolečinam in za zniževanje zvišane telesne tempreature, kakor tudi za preprečevanje strjevanja krvi).
Hydroxypropylcellulose (E463) Titanium dioxide (E171) Red iron oxide (E172) Talc 
hipromeloza (E464) titanov dioksid (E171)
There may be genetic variants of other CYP450 enzymes with effects on the ability to form the active metabolite of clopidogrel. 
Mogoče je, da obstajajo tudi genetske različice drugih encimov CYP450, ki vplivajo na zmožnost tvorbe aktivnega presnovka klopidogrela.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. 
Absorpcija Po enkratnem in večkratnih peroralnih odmerkih po 75 mg na dan se klopidogrel hitro absorbira
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used. 
Ta koristni učinek se je pojavljal v vseh prehodno opredeljenih podskupinah glede na bolnikovo starost ali spol, mesto infarkta in tip uporabljenega fibrinolitika ali heparina.
Lower active metabolite exposure results in less platelet inhibition or higher residual platelet reactivity. 
Manjša izpostavljenost aktivnemu presnovku povzroči manjše zavrtje trombocitov ali večjo rezidualno reaktivnost trombocitov.
Further information 
DODATNE INFORMACIJE
Pregnancy and breast-feeding It is preferable not to use this product during pregnancy and breast-feeding. 
Nosečnost in dojenje Priporočljivo je, da tega zdravila ne jemljejo nosečnice in matere, ki dojijo.
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. 
V študijo CLARITY je bilo vključenih 3.491 bolnikov v 12 urah po nastopu akutnega miokardnega infarkta z elevacijo ST spojnice, ki so bili predvideni za trombolitično terapijo.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity. 
Klopidogrel so preizkušali v številnih in vitro ter in vivo študijah genotoksičnosti in niso ugotovili nobenega genotoksičnega učinka.
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge. 
Pri bolnikih, pri katerih ni bila opravljena angiografija, sta bila primarna opazovana dogodka smrt ali ponovni miokardni infarkt do 8. dneva oziroma do odpusta.
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolnike, ki jemljejo klopidogrel (samega ali v kombinaciji z ASA), je treba opozoriti, da je lahko čas, ki je potreben za zaustavitev krvavitve, daljši kot ponavadi, in da morajo svojemu zdravniku poročati o kakršnikoli neobičajni krvavitvi (o mestu ali trajanju).
TEVA PHARMA, S.L.U. 
España TEVA PHARMA, S.L.U.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
Po peroralnem odmerku s 14C označenega klopidogrela pri človeku se ga je v 120-urnem intervalu po odmerjanju približno 50%% izločilo s sečem in približno 46% z blatom.
Reduced CYP2C19 metabolism in intermediate and poor metabolisers decreased the Cmax and AUC of the active metabolite by 30-50% following 300- or 600-mg loading doses and 75-mg maintenance doses. 
Zmanjšana presnova s CYP2C19 pri srednjih in slabih presnavljalcih je po 300- ali 600-mg polnilnem odmerku in 75-mg vzdrževalnem odmerku zmanjšala Cmax in AUC aktivnega presnovka za 30 do 50%.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%). 
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3%; IZ: 24,3%, 57,5%) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2%; IZ: 6,5%, 28,3%).
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni opazovani dogodki so bili navzočnost kompozita (zaradi infarkta zamašene arterije) na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
Pharmacogenetics: Based on literature data, patients with genetically reduced CYP2C19 function have lower systemic exposure to the active metabolite of clopidogrel and diminished antiplatelet responses, and generally exhibit higher cardiovascular event rates following myocardial infarction than do patients with normal CYP2C19 function (see section 5.2). 
Farmakogenetika: Podatki iz literature kažejo, da imajo bolniki z genetsko zmanjšano funkcijo CYP2C19 manjšo sistemsko izpostavljenost aktivnemu presnovku klopidogrela in manjše antitrombocitne odzive; delež kardiovaskularnih dogodkov po miokardnem infarktu je pri teh bolnikih na splošno večji kot pri bolnikih z normalnim delovanjem CYP2C19 (glejte poglavje 5.2).
There was no excess in major bleeds with clopidogrel + ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery (4.4% clopidogrel + ASA vs. 5.3% placebo + ASA). 
Število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v sedmih dneh po koronarni premostitveni operaciji pri bolnikih, ki so zdravljenje prekinili več kot pet dni pred kirurškim posegom (klopidogrel in ASA: 4,4%%; placebo in ASA 5,3%%).
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
Klopidogrel se in vitro in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami in povzroči hidrolizo v neaktiven karboksilnokislinski derivat (85% presnovkov v obtoku), druga pa z več encimi citokroma P450.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+ASA, and 6.3% for placebo + ASA. 
Pri bolnikih, ki so se zdravili do pet dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6%% za klopidogrel in ASA in 6,3%% za placebo in ASA.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. 
V stanju dinamičnega ravnovesja je bila povprečna raven zaviranja z odmerkom 75 mg na dan 40- do 60%.
• if you suffer from severe liver disease. 
• če imate hudo jetrno obolenje.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Po večkratnih odmerkih 75 mg klopidogrela na dan pri osebah s hudo ledvično boleznijo (kreatininski očistek 5-15 ml/min) inhibicija z ADP-jem sprožene agregacije trombocitov manjša (25%%) od tiste, opažene pri zdravih osebah.Vendar je bilo podaljšanje časa krvavitve podobno tistemu, ki so ga opazili pri zdravih osebah, ki so jemale 75 mg klopidogrela na dan.
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
• Ledvična okvara Terapevtske izkušnje pri bolnikih z ledvično okvaro so omejene (glejte poglavje 4.4).
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis). 
Zaviralci agregacije trombocitov preprečujejo to zlepljanje in s tem zmanjšajo možnost za nastanek krvnih strdkov (proces se imenuje tromboza).
Patients were randomized to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years. 
Bolniki so bili naključno razdeljeni v skupine, ki so jemale 75 mg klopidogrela na dan ali 325 mg ASA na dan, spremljali so jih od 1 leto do 3 leta.
28 film-coated tablets 28x1 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets 56x1 film-coated tablets 84 film-coated tablets 84x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets 
28 filmsko obloženih tablet 28x1 filmsko obložena tableta 30 filmsko obloženih tablet 30x1 filmsko obložena tableta 50 filmsko obloženih tablet 50x1 filmsko obložena tableta 56 filmsko obloženih tablet 56x1 filmsko obložena tableta 84 filmsko obloženih tablet 84x1 filmsko obložena tableta 90 filmsko obloženih tablet 90x1 filmsko obložena tableta 100 filmsko obloženih tablet 100x1 filmsko obložena tableta
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. 
Pri zdravljenju tega stanja vam je zdravnik v zamašeno ali zoženo arterijo morda moral vstaviti stent (žično opornico), da bi žilo tako razširil in obnovil pretok krvi.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to reduced metabolism. 
Alel CYP2C19*1 ustreza polno funkcionalni presnovi, medtem ko alela CYP2C19*2 in CYP2C19*3 ustrezata zmanjšani presnovi.
The most common side effect (affects 1 to 10 patients in 100) reported with Clopidogrel Teva Generics B.V. is bleeding. 
Najpogostejši neželeni učinek (pojavi se pri 1 do 10 od 100 bolnikov), o katerem so poročali med zdravljenjem z zdravilom Klopidogrel Teva Generics B.V.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
Zdravilo vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V študiji CAPRIE je bila pri bolnikih, ki so se zdravili s klopidogrelom ali z ASA, skupna incidenca vseh krvavitev 9,3%%.
Published frequencies for the common CYP2C19 phenotypes and genotypes are listed in the table below. 
Objavljene pogostnosti pogostih fenotipov in genotipov CYP2C19 so navedene v spodnji preglednici.
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. 
Farmakokinetika digoksina ali teofilina se ob sočasnem jemanju klopidogrela ni spremenila.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects') 
• morate zdravniku takoj povedati, če se pri vas pojavi bolezensko stanje (znano kot tombotična trombocitopenična purpura ali TTP), ki vključuje zvišano telesno temperaturo in modrice pod kožo (pojavijo se kot drobne rdeče pike), nerazložljiva huda utrujenost, zmedenost ter porumenelost kože ali oči (zlatenica) (glejte poglavje »Možni neželeni učinki«);
Propylene glycol 
smukec propilenglikol
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. 
Tako kot druge antitrombotike tudi klopidogrel previdno uporabljamo pri bolnikih, pri katerih zaradi poškodbe, kirurškega posega ali drugih patoloških stanj obstaja tveganje za povečano krvavitev, in pri bolnikih, ki so na zdravljenju z ASA, s heparinom, z zaviralci glikoproteina IIb/IIIa ali z nesteroidnimi protivnetnimi zdravili (NSAID), vključno z zaviralci ciklooksigenaze-2 (COX-2).
This could potentially lead to increased plasma levels of medicinal products such as phenytoin and tolbutamide and the NSAIDs, which are metabolised by Cytochrome P450 2C9. 
To lahko povzroči povečano plazemsko koncentracijo fenitoina in tolbutamida ter nesteroidnih protivnetnih zdravil, ki se presnavljajo s citokromom P450 2C9.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni presnovek klopidogrela selektivno zavira vezavo adenozin-difosfata (ADP) na njegov trombocitni receptor P2Y12 in nadaljnjo aktivacijo glikoproteinskega kompleksa GP IIb/IIIa z
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. 
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišane srčne encime ali troponin I ali T
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. 
CYP2C19 je vključen tako v nastajanje aktivnega presnovka kot vmesnega presnovka, 2-oksoklopidogrela.
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
• Z akutnim koronarnim sindromom: Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
Akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia. 
Študija CURE je vključevala 12.562 bolnikov z akutnim koronarnim sindromom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca) do 24 ur po zadnji epizodi bolečine v prsih ali simptomih, konsistentnih z ishemijo.
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see sections 4.4 and 5.2). 
Iz previdnosti naj sočasno ne bi uporabljali zdravil, ki zavirajo CYP2C19 (glejte poglavji 4.4 in 5.2).